v3.26.1
Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)
 3 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Braingenesis Biotechnology Co., Ltd. [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 0.17% 0.17%
Accounting treatments Cost Method  
Genepharm Biotech Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage [1] 0.39% 0.67%
Accounting treatments [1] Cost Method  
BioHopeKing Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 5.90% 5.90%
Accounting treatments Cost Method  
ForSeeCon Eye Corporation (see Note 10) [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 19.78% 19.78%
Accounting treatments Cost Method  
BioFirst Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 18.68% 18.68%
Accounting treatments Equity Method  
OncoX BioPharma, Inc. (see Note 10) [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 24.97% 24.97%
Accounting treatments Equity Method  
Rgene Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 37.00% 37.00%
Accounting treatments Equity Method  
BioLite Japan K.K. [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 49.00% 49.00%
Accounting treatments Equity Method  
[1] This company was acquired by Canal Biotech Corporation Inc., and upon completion of the acquisition, the Company’s ownership percentage is determined to be 0.39% The Company’s stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.